Research Articles - Macular Degeneration
StemCells, Inc. , which launched a Phase I/II clinical trial for its dry age-related macular degeneration (AMD) therapy in October 2012, has begun administering the highest dose of its treatment to patients in the study. The fifth patient in the trial has received a transplant of one million of the company’s human neural stem cells known as HuCNS-SC ® .
Researchers from the University of Wisconsin School of Medicine and Public Health have determined that people taking commonly prescribed blood-pressure medications — including drugs that open and relax blood vessels and regulate heart rhythm — appear to be at increased risk for age-related macular degeneration (AMD). The findings are based on an analysis of data from a long-term study of approximately 5,000 residents of Beaver Dam, Wisconsin, funded by the National Eye Institute.
Though age-related macular degeneration (AMD) is a highly prevalent and blinding retinal disease affecting more than 10 million Americans, its cause has been a tough nut for researchers to crack, because of the multiple genetic and lifestyle factors that come into play. For decades, getting to the root causes of AMD has been challenging.
But in a research paper published in the October 6, 2011 journal Nature, an international group of scientists, including the Foundation-funded investigator
- Researchers have determined that identifying the genes linked to a person’s wet age-related macular degeneration (AMD) does not predict how well the drugs Lucentis® or Avastin® will save or restore their vision. Their findings are based on an analysis of people participating in the Comparison of AMD Treatment Trials (CATT). Results of the analysis were published in January in the journal Ophthalmology.
Acucela Inc., a Seattle-based developer of eye-disease therapies, is enrolling 440 patients across 56 sites for its three-year, Phase 2b/3 clinical trial of emixustat hydrochloride (formerly ACU-4429) for the treatment of advanced dry age-related macular degeneration (AMD), a vision-robbing retinal condition also known as geographic atrophy (GA). In August, the company reported that it reached 50 percent enrollment for the study.
A new study published in the journal Ophthalmology indicates that the beneficial effects of Lucentis, a popular treatment for wet age-related macular degeneration (AMD) developed by Genentech, may diminish over time for some patients. While Lucentis stabilized or improved vision in 90 percent of people with wet AMD participating in two-year clinical trials, study results